Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.
You may also be interested in...
A 'complete shift' in diabetes prescribing practices toward cardiovascular protective agents is occurring more slowly than anticipated, but Cleveland Clinic Cardiology chief Steve Nissen is ready to claim success in decade-long effort to shift diabetes drug treatment focus from blood sugar to cardiovascular mortality.
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
Johnson & Johnson and Roche launched the big pharma quarterly reporting season. Next up are Novartis, Lilly, Merck, Bayer, GSK, Bristol-Myers Squibb, Amgen and Sanofi. Scrip offers some key points to watch for.